Pasithea therapeutics announces $5 million private placement priced at-the-market under nasdaq rules

Miami, sept. 26, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,219,513 shares of its common stock (or pre-funded warrants in lieu thereof), accompanying series a warrants to purchase up to 1,219,513 shares of common stock and accompanying short-term series b warrants to purchase up to 1,219,513 shares of common stock at a purchase price of $4.10 per share (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the nasdaq stock market. the series a and the short-term series b warrants will have an exercise price of $3.85 per share and will be exercisable immediately upon issuance. the series a warrants will expire five years from the issuance date and the short-term series b warrants will expire 18 months from the issuance date. the closing of the offering is expected to occur on or about september 30, 2024, subject to the satisfaction of customary closing conditions.
KTTA Ratings Summary
KTTA Quant Ranking